This report provides an analysis of strategic transactions encompassing licensing, acquisitions and collaborations in the global biomarker market. It focuses on deals executed between 2019 and 2025, providing a retrospective assessment of deal-making activity to identify emerging trends, investment behaviors and strategic priorities in the biomarker landscape.
The biomarker deals are gaining considerable momentum amid the rapid shift toward precision medicine, increased investment in targeted drug development and greater collaboration among biotech companies, diagnostic developers and pharmaceutical firms. Biomarkers are measurable indicators that reflect normal or abnormal biological processes, disease progression or response to therapeutic interventions. They are critical to improving clinical outcomes, accelerating drug approvals and reducing development costs. Biomarker deals include licensing deals, acquisitions, and collaborative agreements in high-impact areas like oncology, neurology, immunology and infectious disease. The deals reflect the
rising demand for companion diagnostics, predictive biomarkers and methods of detection that leverage emerging technologies in therapeutics and diagnostics.
The chosen time frame reflects the factual nature of deal terms, values and structures, which cannot be accurately forecast. The report provides insights into terms of contracts, such as up-front payments, milestone-based compensation, royalty arrangements and termination clauses, supported by real-world case examples.
In addition to transaction analysis, the report provides an in-depth review of market dynamics, highlighting the drivers, restraints, opportunities and challenges influencing the market for biomarker development and commercialization. It also covers emerging technologies in the sector.
Overall, this report serves as a resource for prospective dealmakers seeking to understand the current state of biomarker partnerships. It offers actionable insights into how companies are structuring collaborations for the R&D and commercialization of biomarker technologies, supporting informed decision-making in this rapidly evolving field.
The biomarker deals are gaining considerable momentum amid the rapid shift toward precision medicine, increased investment in targeted drug development and greater collaboration among biotech companies, diagnostic developers and pharmaceutical firms. Biomarkers are measurable indicators that reflect normal or abnormal biological processes, disease progression or response to therapeutic interventions. They are critical to improving clinical outcomes, accelerating drug approvals and reducing development costs. Biomarker deals include licensing deals, acquisitions, and collaborative agreements in high-impact areas like oncology, neurology, immunology and infectious disease. The deals reflect the
rising demand for companion diagnostics, predictive biomarkers and methods of detection that leverage emerging technologies in therapeutics and diagnostics.
Report Scope
This report, Biomarker Deals: Terms, Value and Trends 2019-2025, offers a comprehensive analysis of strategic transactions, encompassing licensing, acquisitions and collaborations, in the global biomarkers industry. It focuses on deals executed between 2019 and 2025, providing a retrospective assessment of deal-making activity to identify emerging trends, investment behaviors and strategic priorities in the biomarker landscape.The chosen time frame reflects the factual nature of deal terms, values and structures, which cannot be accurately forecast. The report provides insights into terms of contracts, such as up-front payments, milestone-based compensation, royalty arrangements and termination clauses, supported by real-world case examples.
In addition to transaction analysis, the report provides an in-depth review of market dynamics, highlighting the drivers, restraints, opportunities and challenges influencing the market for biomarker development and commercialization. It also covers emerging technologies in the sector.
Overall, this report serves as a resource for prospective dealmakers seeking to understand the current state of biomarker partnerships. It offers actionable insights into how companies are structuring collaborations for the R&D and commercialization of biomarker technologies, supporting informed decision-making in this rapidly evolving field.
Report Includes
- An overview of the current state of the biomarker industry, recent licensing deals, and collaborations and acquisitions in the market, including a comprehensive analysis of deal structures and their potential values
- Coverage of significant companies in this study, trends and obstacles and other information affecting the development of the biomarker market
- Review of business terms and conditions of deals in the market, with focus on major trends in deal-making, the companies involved and analysis of further potential in out-licensing, collaboration and acquisition opportunities
- Information essential to a prospective dealmaker about partnering in the research, development and commercialization of biomarker technologies and products.
- Information about the main elements in licensing, acquisitions and partnership deals in the biomarker industry
- Coverage of research methodology employing a triangulating approach and significant details of patent search and analysis, clinical trial search and analysis, et al.
- Details on various types of biomarkers deals and milestone payments and their value in different deals
- Analysis of the patent landscape featuring biomarkers
- Profiles of the leading companies, including Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Illumina Inc., Bio-Rad Laboratories Inc., and Agilent Technologies Inc.
Table of Contents
Chapter 1 Executive Summary
Chapter 2 Market Overview
Chapter 3 Market Dynamics
Chapter 4 Emerging Technologies and Developments
Chapter 5 Acquisitions, Collaborations, and Licensing Deals
Chapter 6 Biomarker Patent Landscape
Chapter 7 Appendix
List of Tables
List of Figures
Companies Mentioned
- Abbott
- Agilent Technologies Inc.
- Bayer Ag
- BD
- Biofourmis
- Biomerieux
- Bio-Rad Laboratories Inc.
- Bruker
- Danaher Corp.
- F. Hoffmann-La Roche Ltd.
- Illumina Inc.
- Merck Kgaa
- Qiagen
- Revvity
- Thermo Fisher Scientific Inc.
